Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoblastoma - Overview
Retinoblastoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Retinoblastoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoblastoma - Companies Involved in Therapeutics Development
Aileron Therapeutics Inc
APEIRON Biologics AG
Ascentage Pharma Group Intertiol
Canget BioTekpharma LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cothera Bioscience Pty Ltd
Innovation Pharmaceuticals Inc
Oxular Ltd
PepVax Inc
Seneca Therapeutics Inc
Spectocular LLC
Targeted Therapy Technologies LLC
VCN Biosciences SL
Retinoblastoma - Drug Profiles
APG-115 - Drug Profile
Product Description
Mechanism Of Action
History of Events
conbercept - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug to Inhibit MDM2 for Retinoblastoma - Drug Profile
Product Description
Mechanism Of Action
History of Events
FL-761 - Drug Profile
Product Description
Mechanism Of Action
FL-7729 - Drug Profile
Product Description
Mechanism Of Action
FL-7N1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Kevetrin - Drug Profile
Product Description
Mechanism Of Action
History of Events
lorukafusp alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
OXU-003 SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
PC-002p - Drug Profile
Product Description
Mechanism Of Action
PVX-301 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sulanemadlin - Drug Profile
Product Description
Mechanism Of Action
History of Events
SVV-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
topotecan - Drug Profile
Product Description
Mechanism Of Action
History of Events
VCN-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Retinoblastoma - Dormant Projects
Retinoblastoma - Product Development Milestones
Featured News & Press Releases
Feb 08, 2022: Synthetic Biologics announces VCN Biosciences’ VCN-01 receives orphan drug desigtion for retinoblastoma from the U.S. FDA
Oct 12, 2020: Oxular Receives Rare Paediatric Disease and Orphan-Drug Desigtions for retinoblastoma treatment
Jan 24, 2019: SJD Barcelo Children’s Hospital is, for the first time in the world, treating a childhood cancer of the reti with the oncolytic virus VCN-01
Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01
Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Desigtion From FDA for Kevetrin for the Treatment of Retinoblastoma
Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Desigtion for Kevetrin for the Treatment of Retinoblastoma
Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
Oct 31, 2012: VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Retinoblastoma, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Retinoblastoma, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Retinoblastoma - Pipeline by Aileron Therapeutics Inc, 2022
Retinoblastoma - Pipeline by APEIRON Biologics AG, 2022
Retinoblastoma - Pipeline by Ascentage Pharma Group International, 2022
Retinoblastoma - Pipeline by Canget BioTekpharma LLC, 2022
Retinoblastoma - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022
Retinoblastoma - Pipeline by Cothera Bioscience Pty Ltd, 2022
Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, 2022
Retinoblastoma - Pipeline by Oxular Ltd, 2022
Retinoblastoma - Pipeline by PepVax Inc, 2022
Retinoblastoma - Pipeline by Seneca Therapeutics Inc, 2022
Retinoblastoma - Pipeline by Spectocular LLC, 2022
Retinoblastoma - Pipeline by Targeted Therapy Technologies LLC, 2022
Retinoblastoma - Pipeline by VCN Biosciences SL, 2022
Retinoblastoma - Dormant Projects, 2022